Quest Diagnostics

Report Status: Final

KHANNA, MANSI

Patient Information	Specimen Information	Client Information
KHANNA, MANSI **DOB: 09/23/1995 AGE: 26** Gender: F Phone: NG Patient ID: 203004526	Specimen: CF100135V Requisition: 5860959 Lab Ref #: 3558985 Collected: 03/18/2022 / 14:37 EDT Received: 03/18/2022 / 22:22 EDT Reported: 03/21/2022 / 11:54 EDT	Client #: 48023493 NYNJMAIL SANDERS, LESLIE COOK-DOUGLAS HEALTH CENTER Attn: RUTGERS UNIVERSITY HLTH SERV. 61 DUDLEY RD NEW BRUNSWICK, NJ 08901-8520

CytoComplete™ Pap and/or HPV Results — Lab: P89

THINPREP PAP AND HPV mRNA E6/ E7, CHLAMYDIA/N.GONORRHOEAE

- **Negative for intraepithelial lesion or malignancy.**
- **HPV mRNA E6/E7 Not Detected**

Molecular Test	Result	Reference Range	Endnote	Lab
HPV mRNA E6/E7	Not Detected	Not Detected	1, 2	Z99
CHLAMYDIA TRACHOMATIS RNA, TMA, UROGENITAL	NOT DETECTED	NOT DETECTED	3	Z99
NEISSERIA GONORRHOEAE RNA, TMA, UROGENITAL	NOT DETECTED	NOT DETECTED	3	Z99

ADEQUACY

Satisfactory for evaluation. Endocervical/ transformation zone component present.
Age and/or menstrual status not provided
Source: None given

COMMENTS

CLINICAL INFORMATION

None given
LMP: None given
prev. Pap: None given
prev. Bx: None given

Cytotechnologist: MXH, CT(ASCP) CT Screening Location: Quest Philadelphia 400 Egypt Road Norristown, PA 19403
Slide Preparation performed at: Quest Diagnostics 1 Insights Drive Clifton, NJ 07012 CLIA No.: 31D0696246

Endnote 1 Methodology: Transcription-Mediated Amplification
This assay detects E6/E7 viral messenger RNA (mRNA) from 14 high-risk HPV types (16,18,31,33,35,39,45,51,52,56,58,59,66,68).

Endnote 2 The analytical performance characteristics of this assay have been determined by Quest Diagnostics. The modifications have not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ129v1 (This link if provided for information/ educational purposes only.)

Endnote 3 The analytical performance characteristics of this assay, when used to test SurePath(TM) specimens have been determined by Quest Diagnostics. The modifications have not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
For additional information, please refer to https://education.questdiagnostics.com/faq/FAQ154 (This link is being provided for information/ educational purposes only.)

For questions contact Anatomic Pathology Client Services at 215-444-8200 and reference DEPT ID: CC228266660

EXPLANATORY NOTE: The Pap is a screening test for cervical cancer. It is not a diagnostic test and is subject to false negative and false positive results. It is most reliable when a satisfactory sample, regularly obtained, is submitted with relevant clinical findings and history, and when the Pap result is evaluated along with historic and current clinical information.

PERFORMING SITE:

P89 QUEST DIAGNOSTICS PHILADELPHIA, 400 EGYPT ROAD CLINICAL LAB, NORRISTOWN, PA 19403-3406 Laboratory Director: ANDREW EDELMAN,MD,PHD, CLIA: 39D0204404
Z99 QUEST DIAGNOSTICS CLIFTON, 1 INSIGHTS DRIVE, CLIFTON, NJ 07012-2355 Laboratory Director: SHELLA K MONGIA,MD, CLIA: 31D0696246